Mark R Hanudel1, Marciana Laster2, Georgina Ramos2, Barbara Gales2, Isidro B Salusky2. 1. Department of Pediatrics, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, MDCC A2-383, Los Angeles, CA, 90095-1752, USA. mhanudel@mednet.ucla.edu. 2. Department of Pediatrics, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, MDCC A2-383, Los Angeles, CA, 90095-1752, USA.
Abstract
BACKGROUND: Ferric citrate, an iron-based phosphate binder, has been shown to improve both hyperphosphatemia and iron deficiency in adult chronic kidney disease patients, but its use in the pediatric dialysis population has not been described. METHODS: This is a retrospective analysis of 11 unselected pediatric dialysis patients who received ferric citrate as a phosphate binder between 2015 and 2017. Time-averaged laboratory values were compared pre- and post-ferric citrate initiation using the Wilcoxon signed-rank test. RESULTS: The median age of this cohort was 13 years old (range 4-17 years old). Five patients were on hemodialysis, and six patients were on peritoneal dialysis. The median duration of ferric citrate therapy was 214 days (range 39-654 days), with a median time-averaged ferric citrate dose of 3.5 tablets per day (range 1.5-8.4 tablets per day). Compared to the pre-ferric citrate period, ferric citrate treatment was associated with decreased serum phosphate (6.5 to 5.2 mg/dl, p = 0.014), decreased phosphate age-related standard deviation score (SDS) (2.3 to 0.9, p = 0.019), increased transferrin saturation (26 to 34%, p = 0.049), increased ferritin (107 to 230 ng/ml, p = 0.074), and maintenance of hematocrit. CONCLUSIONS: In pediatric dialysis patients, ferric citrate may be able to concurrently lower phosphate levels and treat iron deficiency. However, larger studies are needed to further evaluate safety and efficacy in the pediatric chronic kidney disease population.
BACKGROUND: Ferric citrate, an iron-based phosphate binder, has been shown to improve both hyperphosphatemia and iron deficiency in adult chronic kidney disease patients, but its use in the pediatric dialysis population has not been described. METHODS: This is a retrospective analysis of 11 unselected pediatric dialysis patients who received ferric citrate as a phosphate binder between 2015 and 2017. Time-averaged laboratory values were compared pre- and post-ferric citrate initiation using the Wilcoxon signed-rank test. RESULTS: The median age of this cohort was 13 years old (range 4-17 years old). Five patients were on hemodialysis, and six patients were on peritoneal dialysis. The median duration of ferric citrate therapy was 214 days (range 39-654 days), with a median time-averaged ferric citrate dose of 3.5 tablets per day (range 1.5-8.4 tablets per day). Compared to the pre-ferric citrate period, ferric citrate treatment was associated with decreased serum phosphate (6.5 to 5.2 mg/dl, p = 0.014), decreased phosphate age-related standard deviation score (SDS) (2.3 to 0.9, p = 0.019), increased transferrin saturation (26 to 34%, p = 0.049), increased ferritin (107 to 230 ng/ml, p = 0.074), and maintenance of hematocrit. CONCLUSIONS: In pediatric dialysis patients, ferric citrate may be able to concurrently lower phosphate levels and treat iron deficiency. However, larger studies are needed to further evaluate safety and efficacy in the pediatric chronic kidney disease population.
Entities:
Keywords:
CKD-MBD; Dialysis; Ferric citrate; Iron deficiency; Pediatric; Phosphate
Authors: Rupal Mehta; Xuan Cai; Jungwha Lee; Julia J Scialla; Nisha Bansal; James H Sondheimer; Jing Chen; L Lee Hamm; Ana C Ricardo; Sankar D Navaneethan; Rajat Deo; Mahboob Rahman; Harold I Feldman; Alan S Go; Tamara Isakova; Myles Wolf Journal: JAMA Cardiol Date: 2016-08-01 Impact factor: 14.676
Authors: Geoffrey A Block; Steven Fishbane; Mariano Rodriguez; Gerard Smits; Shay Shemesh; Pablo E Pergola; Myles Wolf; Glenn M Chertow Journal: Am J Kidney Dis Date: 2014-11-04 Impact factor: 8.860
Authors: Orlando M Gutiérrez; Michael Mannstadt; Tamara Isakova; Jose Alejandro Rauh-Hain; Hector Tamez; Anand Shah; Kelsey Smith; Hang Lee; Ravi Thadhani; Harald Jüppner; Myles Wolf Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245
Authors: Danilo Fliser; Barbara Kollerits; Ulrich Neyer; Donna P Ankerst; Karl Lhotta; Arno Lingenhel; Eberhard Ritz; Florian Kronenberg; Erich Kuen; Paul König; Günter Kraatz; Johannes F E Mann; Gerhard A Müller; Hans Köhler; Peter Riegler Journal: J Am Soc Nephrol Date: 2007-07-26 Impact factor: 10.121
Authors: Domenico Girelli; Paola Trombini; Fabiana Busti; Natascia Campostrini; Marco Sandri; Sara Pelucchi; Mark Westerman; Tomas Ganz; Elizabeta Nemeth; Alberto Piperno; Clara Camaschella Journal: Haematologica Date: 2010-12-20 Impact factor: 9.941
Authors: Valentin David; Aline Martin; Tamara Isakova; Christina Spaulding; Lixin Qi; Veronica Ramirez; Kimberly B Zumbrennen-Bullough; Chia Chi Sun; Herbert Y Lin; Jodie L Babitt; Myles Wolf Journal: Kidney Int Date: 2016-01-04 Impact factor: 10.612
Authors: Mark R Hanudel; Marciana L Laster; Anthony A Portale; Aditi Dokras; Raymond P Quigley; German A Lozano Guzman; Joshua J Zaritsky; Nicole A Hayde; Frederick J Kaskel; Mark M Mitsnefes; Jorge A Ramirez; Peace D Imani; Poyyapakkam R Srivaths; Amy J Kogon; Michelle R Denburg; Tom D Blydt-Hansen; Loretta Z Reyes; Larry A Greenbaum; Darcy K Weidemann; Bradley A Warady; David A Elashoff; Susan R Mendley; Tamara Isakova; Isidro B Salusky Journal: Pediatr Nephrol Date: 2022-03-02 Impact factor: 3.651